Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. [electronic resource]
Producer: 20061030Description: 4699-707 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carboplatin -- administration & dosage
- Cisplatin -- pharmacology
- Deoxycytidine -- administration & dosage
- Disease Progression
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Quality of Life
- Survival Analysis
- Treatment Outcome
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.